Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy

Immune check point inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum failure [1]. In many tumors, anti PD1 or anti PDL 1 have increased median overall survival (OS) but have not demonstrated greater median progression free survival (PFS) [1–3]. Recent data has suggested that chemotherapy in post-nivolumab treatment may induce better objective responses than historical data did [4].

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2HUqFK5